CIK 0001824893 · Non-accelerated filer<br>Smaller reporting company
Surrozen, Inc./DE
Sign in to watch- Ticker
- SRZN
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 301374889
- Phone
- 650-475-2820
- Business address
- 171 OYSTER POINT BLVD, SUITE 400, SOUTH SAN FRANCISCO, CA, 94080
- Former names
- Consonance-HFW Acquisition Corp.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Reading 54 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-01-14 | Kutzkey Tim Director | Purchase | +2,596 | $19.99 | $52K | 885,014 |
| 2026-01-14 | Kutzkey Tim Director | Purchase | +2,927 | $19.99 | $59K | 999,429 |
| 2026-01-14 | COLUMN GROUP III GP, LP 10% owner | Purchase | +2,596 | $19.99 | $52K | 885,014 |
| 2026-01-14 | COLUMN GROUP III GP, LP 10% owner | Purchase | +2,927 | $19.99 | $59K | 999,429 |
| 2026-01-13 | Kutzkey Tim Director | Purchase | +5,861 | $19.80 | $116K | 882,418 |
| 2026-01-13 | Kutzkey Tim Director | Purchase | +6,609 | $19.80 | $131K | 996,502 |
| 2026-01-13 | COLUMN GROUP III GP, LP 10% owner | Purchase | +5,861 | $19.80 | $116K | 882,418 |
| 2026-01-13 | COLUMN GROUP III GP, LP 10% owner | Purchase | +6,609 | $19.80 | $131K | 996,502 |
| 2026-01-06 | COLUMN GROUP III GP, LP 10% owner | Purchase | +7,097 | $19.89 | $141K | 876,557 |
| 2026-01-06 | COLUMN GROUP III GP, LP 10% owner | Purchase | +8,003 | $19.89 | $159K | 989,893 |
| 2026-01-06 | Kutzkey Tim Director | Purchase | +7,097 | $19.89 | $141K | 876,557 |
| 2026-01-06 | Kutzkey Tim Director | Purchase | +8,003 | $19.89 | $159K | 989,893 |
| 2026-01-05 | Li Yang Exec. Vice President, Research | Sale | −1,118 | $19.87 | $22K | 16,091 |
| 2026-01-05 | Williams Charles O Chief Operating Officer | Sale | −1,566 | $19.87 | $31K | 12,982 |
| 2026-01-02 | Li Yang Exec. Vice President, Research | Option exercise | +2,500 | 17,209 | ||
| 2026-01-02 | Li Yang Exec. Vice President, Research | Option exercise · Restricted Stock Units | −2,500 | 0 | ||
| 2026-01-02 | Williams Charles O Chief Operating Officer | Option exercise | +3,500 | 14,548 | ||
| 2026-01-02 | Williams Charles O Chief Operating Officer | Option exercise · Restricted Stock Units | −3,500 | 0 | ||
| 2025-12-15 | Li Yang Exec. Vice President, Research | Grant or award | +1,666 | $8.11 | $14K | 14,709 |
| 2025-12-15 | Williams Charles O Chief Operating Officer | Grant or award | +1,666 | $8.11 | $14K | 11,048 |
Page 5 of 12 · 237 trades